Navigation Links
Novel marker discovered for stem cells derived from human umbilical cord blood
Date:4/17/2014

New Rochelle, NY, April 17, 2014The development of stem cell therapies to cure a variety of diseases depends on the ability to characterize stem cell populations based on cell surface markers. Researchers from the Finnish Red Cross have discovered a new marker that is highly expressed in a type of stem cells derived from human umbilical cord blood, which they describe in an article in BioResearch Open Access, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the BioResearch Open Access website.

Heli Suila and colleagues, Finnish Red Cross Blood Service, Helsinki, Finland present evidence to show that the glycan O-GLcNAc, is present on the surface of stem cells and is part of a stem cell-specific surface signature. In the article "Extracellular O-Linked N-Acetylglucosamine Is Enriched in Stem Cells Derived from Human Umbilical Cord Blood" the authors suggest that the glycan plays a crucial role in a cell signaling pathway that regulates embryonic development.

"This work is particularly interesting as epidermal growth factor domains are found on the Notch receptors, suggesting that these novel glycans may be involved in Notch receptor signaling pathways in stem cells," says BioResearch Open Access Editor Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100 x2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1

Related biology news :

1. Researchers discover novel therapy for Crohns disease
2. New clinical trial explores novel noninvasive colon cancer screening test
3. Notre Dame researchers using novel method to combat malaria drug resistance
4. Unique adaptations to a symbiotic lifestyle reveal novel targets for aphid insecticides
5. Key proteins newly discovered form and function may provide novel cancer treatment target
6. Novel discovery by NUS scientists paves the way for more effective treatment of cancers
7. London researchers discover novel mechanism involved in key immune response
8. Mexican rock heroes trial novel green trading system
9. VTT and GE Healthcare developing novel biomarkers to predict Alzheimers disease
10. Cleveland Clinic researchers receive $5 million grant to discover novel pathways to heart disease
11. Novel nano-structures to realize hydrogens energy potential
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel marker discovered for stem cells derived from human umbilical cord blood
(Date:3/20/2017)... -- PMD Healthcare announces the release of its new ... (WMS), a remote, real-time lung health monitoring and management ... a Medical Device, Digital Health, and Chronic Care Management ... solutions that empower people to improve their healthcare and ... the first ever personal spirometer, Spiro PD, which was ...
(Date:3/7/2017)... , March 7, 2017 Brandwatch , the ... by The Prince,s Trust to uncover insights to support ... The Trust. The UK,s leading youth charity will be ... campaign results and get a better understanding of the topics and ... ...
(Date:3/2/2017)... -- Who risk to be deprived of its imprint ... https://www.reportbuyer.com/product/4313699/ WILL APPLE AND SAMSUNG CONFRONT ... sensors using capacitive technology represent a fast growing market, ... an increase of 360% of the number of fingerprint ... sensor market between 2014 and 2017 (source : N+1 ...
Breaking Biology News(10 mins):
(Date:3/20/2017)... , ... March 20, 2017 , ... ... HEPARIN calibration verification / linearity test kit has received US FDA 510(k) clearance ... VALIDATE® HEPARIN kit evaluates Heparin Anti-Xa activity in a human plasma matrix. ...
(Date:3/20/2017)... NEW YORK , March 20, 2017  Attorney Advertising ... behalf of purchasers of the BioAmber Inc. ("BioAmber" or the "Company") ... obtain additional information and assist the investigation by visiting the ... concerns whether BioAmber and certain of its officers and/or directors ... Act of 1934. ...
(Date:3/19/2017)...  Array BioPharma Inc. (Nasdaq: ARRY ) ... Food and Drug Administration,s (FDA) Division of Oncology Products ... for the treatment of NRAS -mutant melanoma, a ... This action was based on thorough discussions and communications ... approval, and followed the late cycle review meeting held ...
(Date:3/18/2017)... , March 17, 2017  A new study ... who historically have been considered ineligible for curative ... reirradiation using intensity-modulated proton therapy (IMPT) for lung ... patients were free from local recurrence at one ... ten patients experienced severe side effects. The study ...
Breaking Biology Technology: